Acute Hemorrhagic Leucoencephalitis (AHLE): A Rare CNS Presentation of Mycoplasma pneumoniae

S.K. Jakaria Been Sayeed 1, Md Moniruzzaman 2, Reaz Mahmud 3, Mohammad B. Rashid 2, Subir Chandra Das 4

Abstract

Acute hemorrhagic leucoencephalitis (AHLE) is a rare inflammatory disease of the brain. Literature on the presentation and management of this rare disease is limited. A Mycoplasma pneumoniae infection is considered a possible trigger for acute hemorrhagic leucoencephalitis (Weston-Hurst syndrome). We report a case of a 58-year-old man presenting with an altered level of consciousness following a history of acute respiratory tract infection. He had also clinical and laboratory features of disseminated intravascular coagulation (DIC). Brain imaging was suggestive of hemorrhagic encephalitis involving both the fronto-temporo-parieto-occipital lobes involving the cortical, subcortical, and splenium of the corpus callosum and the posterior limb of the right internal capsule. Antibodies against Mycoplasma were strongly positive in serum. The patient was treated with fresh frozen plasma, broad-spectrum antibiotics, and methylprednisolone. However, the patient died after 17 days of hospitalization probably due to multiorgan failure and brain herniation.

Keywords: ahle, cns presentation, weston-hurst syndrome, mycoplasma pneumoniae, hemorrhagic leucoencephalitis

Introduction

Acute hemorrhagic leucoencephalitis (AHLE) is a severe, rapidly progressive but rare form of acute disseminated encephalomyelitis (ADEM). The hemorrhagic lesion may involve the white matter of the cerebrum, brain stem, cerebellum, or spinal cord. The histologic hallmark is perivascular polymorphonuclear infiltrates, small vessel necrosis, and demyelination. It is also known as Weston-Hurst syndrome, according to the name of the first descriptor [1]. The etiology of AHLE is still unknown. An autoimmune reaction due to molecular mimicry with some viral or bacterial pathogen like Herpes simplex (HSV), Varicella zoster (VZV), influenza virus, Epstein bar virus, mumps, Mycoplasma pneumoniae, coronavirus disease 2019 (COVID-19), and dengue virus may trigger the reaction [1-4]. Genetic polymorphisms like Ran Binding Protein (RANBP)-2 variant may predispose autoimmune responses [5]. In contrast to ADEM, it usually affects adults, especially males. The typical presentation of AHLE is a short history of respiratory tract infection followed by a multifocal neurological deficit according to the site of the lesion, features of raised intracranial pressure, the rapid development of coma, and even as a cause of death [1,6]. Mycoplasma pneumoniae is a common pulmonary pathogen that may cause pneumonia with varying severity. The extrapulmonary presentation of the bacteria sometimes overshadows its respiratory manifestations. Although rare, nervous system manifestations, like Guillain-Barré syndrome (GBS), transverse myelitis, encephalitis, optic neuritis, and ADEM, may sometimes be associated with this bacteria. The autoimmune reaction, meaning the development of autoantibody, which reacts with myelin and neural tissue, is responsible for such disease development [6]. There are few case reports of Mycoplasma pneumoniae triggering autoimmune hemorrhagic encephalitis in the medical literature, and none from Bangladesh. Here, we report a confirmed Mycoplasma pneumoniae, causing necrotizing hemorrhagic encephalopathy involving deep cerebral white matter.

Case Presentation

A 58-year-old diabetic, male, was admitted to our hospital with complaints of fever, cough, and shortness of breath for 10 days followed by an altered level of consciousness for the last 1 day. The fever was high-grade, remittent and the cough was productive. Initially, the patient was admitted to a local hospital where he was given antibiotics for seven days for pneumonia. However, his condition deteriorates further due to increased breathlessness. On his 10th day of illness, he became drowsy, icteric, pale, and unable to follow any command. Therefore, he was referred to our hospital for further evaluation. On examination, the patient was found obtunded (Glasgow Coma Scale (GCS) 9/15), anemic, icteric, hypotensive, hypoxic (94%), oliguric, and still had a fever. Signs of meningeal irritation were absent, the optic fundus was normal, and the plantar response was bilaterally extensor. Systemic examinations revealed bronchial breath sound and crepitation in both lungs field. Stigmata of chronic liver disease were absent. Laboratory investigations revealed reduced...
hemoglobin, high mean corpuscular volume (MCV), increased reticulocyte count, evidence of hemolysis in peripheral blood film, positive Coombs test, high C-reactive protein (CRP), elevated bilirubin, liver enzyme, and lactate dehydrogenase (LDH). A tracheal aspirate was taken, and a culture was done; however, the culture revealed no growth. Blood culture was found negative but antibodies against Mycoplasma were found strongly positive in the enzyme-linked immunoassay (ELISA) test. The coagulation profile revealed high prothrombin time (PT), activated partial thromboplastin time (APTT), and D-dimer. CSF study was done after correction of the coagulation profile and revealed elevated protein and glucose, absent oligoclonal band, and PCR for herpes simplex virus (HSV), varicella zoster, Cytomegalovirus (CMV), and tuberculosis was found negative (Table 1).

### Table 1

| Variable                        | Value         | Reference       |
|---------------------------------|---------------|-----------------|
| Hemoglobin                      | 6.8 g/dl      | 12.5-16 g/dl    |
| White cell count                | 19850 / mm3   | 4-11 / mm3      |
| Neutrophil                      | 92 %          | 40-75 %         |
| Lymphocyte                      | 6 %           | 20-40 %         |
| Platelet                        | 35000 / mm3   | 150-450 / mm3   |
| MCV                             | 102 fl        | 76-96 fl        |
| Reticulocyte count              | 4.3 %         | 0.5-2 %         |
| Peripheral blood film           | macrocyte, spherocyte, few microcytes, fragmented RBC, thrombocytopenia | |
| ESR                             | 140 mm in 1st hour | 0-10 mm in 1st hour |
| CRP                             | 279.9 mg/L    | < 5 mg/L        |
| Coombs test                     | Positive      |                 |
| LDH                             | 881 U/L       | 100-250 U/L     |
| ALT                             | 287 U / L     | 10-40 U / L     |
| AST                             | 210 U / L     | 8-40 U / L      |
| S. Bilirubin                    | 4.8 mg/dl     | 0.3-1.2 mg/dl   |
| S Creatinine                    | 1.7 mg/dl     | 0.5-1.3 mg/dl   |
| HBsAg, Anti HCV, Anti HAV, Anti HEV, Anti dengue IgM & IgG | Negative | |
| Blood C / S                     | No growth     |                 |
| Urine C/S                       | No growth     |                 |
| Urine DGI for leptosira         | Negative      |                 |
| Antileptospira antibody (IgM, IgG) | Negative | |
| Antimycoplasma Antibody (Ig M, IgG) | ≥ 1: 640 | < 1: 80 |
| RT-PCR for Covid -19            | Negative      |                 |
| CSF Study                       |               |                 |
| Protein                         | 58 mg/dl      | 15-45 mg/dl     |
| Glucose                         | 125 mg/dl     | 40-80 mg/dl     |
| WBC                             | 05            | 0-5/mm3         |
| Lymphocyte                      | 05            |                 |
| Gram, AFB stain                 | Negative      |                 |
| PCR for Herpes simplex, Varicella zoster, Cytomegalovirus, and Tuberculosis | Negative | |
S. Sodium (Na) 130 mmol/L 135-145 mmol/L
S. Potassium (K) 4.5 mmol/L 3.5-4.5 mmol/L
Prothrombin time 100 second 12-17 second
APTT 120 second 28-36 second
D-dimer 15.9 µg/ml < 0.5 µg/ml
FDP 99.3 µg/ml < 0.5 µg/ml

TABLE 1: Laboratory characteristics of the patient during admission at NINS
AST- aspartate deaminase, ALT- alanine deaminase, AFB- acid-fast Bacilli, APTT- activated partial thromboplastin time, CRP- C-reactive protein, C/S- culture & sensitivity, CSF- cerebrospinal fluid, DGI- dark ground immunofluorescence, FDP- fibrin degradation product, HAV- hepatitis A virus, HBsAg- hepatitis B virus surface antigen, HCV- hepatitis C virus, HEV- hepatitis E virus, LDH- lactate dehydrogenase, NINS- National Institute of Neurosciences & Hospital

Chest X-ray revealed bilateral consolidation (Figure 1).

CT scan head revealed intracerebral hemorrhage with multiple mixed-density lesions with perilesional edema (Figure 2).

FIGURE 1: Chest X-ray shows consolidation in both lungs (yellow arrows)
FIGURE 2: CT scan head (non-contrast) showing multiple mixed-density lesions (yellow arrows) all over the cerebral cortex

MRI brain with contrast with perfusion imaging revealed hemorrhagic encephalitis involving both the fronto-temporo-parieto-occipital lobes involving the cortical, subcortical, and splenium of the corpus callosum, the posterior limb of the right internal capsule. Subacute subdural hemorrhage at the right temporo-parieto-occipital convexity (Figure 3).
FIGURE 3: MRI brain (FLAIR sequence) showing predominately hyperintense lesion involving fronto-parieto-temporo-occipital lobes (yellow arrow)

FLAIR- fluid-attenuated inversion recovery

MR perfusion imaging showed partial diffusion restriction restricted areas in both fronto-temporo-parieto-occipital lobes, and gradient recalled echo (GRE) revealed blooming in the above-mentioned area (Figure 4).
Magnetic resonance angiography (MRA) revealed marginal irregularity and a beaded appearance noted at both middle cerebral arteries with distal paucity. However, ICA, ACA, and PCA were found completely normal. MRV was unremarkable.

As the patient’s condition was critical, he was shifted to the intensive care unit and treated with fresh frozen plasma, red blood cell concentrate, broad-spectrum antibiotics (meropenem and moxifloxacin), and methylprednisolone. Although coagulation abnormality was corrected, however, the patient died on the 17th day of hospitalization probably due to multiorgan failure and brain stem herniation.
Discussion

Here, we present a case of acute hemorrhagic leukencephalitis triggered by *Mycoplasma pneumoniae*, the first-ever case reported from Bangladesh. This patient presented with severe pneumonia; subsequently, he developed encephalitis, autoimmune hemolytic anemia, and DIC. Pfausler B et al. [3] reported *Mycoplasma pneumoniae*-related AHLE where both of the patients presented with a short history of upper respiratory tract infection followed by focal neurological deficits like flaccid quadriparesis with unilateral blindness but Rick M et al. [7] described a similar history of upper airway infection followed by an altered level of consciousness with right-sided hemiparesis. Our patient had a similar clinical presentation without any hemiparesis or blindness. The reason behind that was the lesions in the cerebral cortex spare premotor, motor area, and spinal cord. CNS involvement occurs due to an autoimmune reaction, meaning the development of an autoantibody that reacts with myelin and neural tissue is responsible for the disease [3,7]. Tsiodras S et al. reported that the mean interval of CNS manifestation from respiratory infection is nine days (4-14 days) [8], CNS presentation occurred on the 10th day in our patient. Our patient presented with extrapolumary features like hemolysis, thrombocytopenia, elevated liver enzymes, raised bilirubin, and disseminated intravascular coagulation. Common extrapolumary manifestations are described by Kashyap S and Sarkar M [9]. The diagnosis of *M. pneumoniae* is a bit challenging because of the limitations of laboratory tests like difficulty in collecting the sample from the lower respiratory tract. A special technique is needed for culture growth, although sensitivity is only 30-60% [10]. So serological testing is the common mean of diagnosing mycoplasma infection and a four-fold rise in titer between acute and convalescent sera is still considered a ‘gold standard’ to diagnose acute *M. pneumoniae* respiratory infections. Complement fixation tests, enzyme-linked immunoassay, and antigen detection by PCR, immunofluorescence, or immunoblotting are alternative methods of diagnosing mycoplasma infection [9,11]. As we have some limitations in diagnosing mycoplasma infection, we went for a blood culture along with ELISA for detecting circulating antibodies. Blood culture was found negative but ELISA revealed a four-fold rise in immunoglobulin G (IgG) antibody. To exclude other viral infections, including COVID-19, multiplex PCR from CSF was done and found negative. The core diagnostic feature for mycoplasma-induced AHLE is fibrinoid necrosis in the vessel wall with positive immunohistochemistry findings of brain parenchyma [7]. In our patient, it was not possible to perform a brain biopsy and the autopsy was not done due to a religious perspective. Another strong differential of AHLE is acute demyelinating encephalomyelitis. Sometimes, it is difficult to distinguish AHLE from ADEM. We made ADEM, cerebral venous thrombosis, CNS vasculitis, and hemorrhage due to DIC the imaging differentials of the patient. We excluded ADEM by the nature of the MRI lesions; the perilisinal edema of the lesions and associated hemorrhage helped in the exclusion. Brain MRI is highly important and typically reveals confluent white matter lesions with significant edema, petechial hemorrhages, and space-occupying effects. However, there is variability regarding the location of the lesions. Approximately, two-thirds of patients had uni- or bilateral hemispheric involvement, but other distributive patterns have been described. The most useful aspect of cerebral MRI in differentiating AHLE from ADEM is, however, the presence of intraparenchymal hemorrhages [1,6]. Therefore, considering the clinical history, positive laboratory, and radio-imaging (chest X-ray, MRI brain with magnetic resonance venography (MRV), and MRA with contrast) findings diagnosis was made. Treatment of AHLE is immunosuppressive therapy like steroids, cyclophosphamide, rituximab, and plasmapheresis. Even after treatment prognosis is poor. Mortality is around 46.5%, whereas only 14% of patients made a full recovery and 39.5% survived with mild to severe neurological impairment [1]. Although IV methylprednisolone, broad-spectrum antibiotics, and fresh frozen plasma were given for DIC due to severe sepsis, the patient died on the 17th day of his illness. Probably brain stem herniation and sepsis were responsible for the cause of his death. Even after aggressive treatment, mortality is high in AHLE. So early diagnosis and initiation of immunosuppressive therapy are the cornerstones of management.

Conclusions

*Mycoplasma pneumoniae* should be considered a potential cause of encephalitis in adults, especially those with a preceding history of acute respiratory tract infection. Serological testing is more reliable for the diagnosis of the association between encephalitis and *Mycoplasma pneumoniae*.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We are grateful to our patient’s brother who gave informed consent for reporting. Special thanks to Professor Md. Mujibur Rahman Sir for reviewing and further editing our case report.
References

1. Grzonka P, Scholz MC, De Marchis GM, et al.: Acute hemorrhagic leukoencephalitis: a case and systematic review of the literature. Front Neurol. 2020; 11:899. 10.3389/fneur.2020.00899
2. An SF, Groves M, Martinian L, Kuo LT, Scaravilli F: Detection of infectious agents in brain of patients with acute hemorrhagic leukoencephalitis. J Neurovirol. 2002, 8:439-46. 10.1080/13550280260422749
3. Pfaußer B, Engelhardt K, Kampf I, Spiss H, Taferner E, Schmutzhard E: Post-infectious central and peripheral nervous system diseases complicating Mycoplasma pneumoniae infection. Report of three cases and review of the literature. Eur J Neurol. 2002, 9:95-6. 10.1046/j.1468-1331.2002.00550.x
4. Dixon L, Varley J, Gontsarova A, et al.: COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia. Neurol Neuroimmunol Neuroinflamm. 2020, 7:10.1212/NXI.0000000000000789
5. Neilson DE, Adams MD, Orr CM, et al.: Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet. 2009, 84:44-51. 10.1016/j.ajhg.2008.12.009
6. Gibbs WN, Kreidie MA, Kim RC, Hao AN: Acute hemorrhagic leukoencephalitis: neuroimaging features and neuropathologic diagnosis. J Comput Assist Tomogr. 2005, 29:689-93. 10.1097/01.rct.0000173843.82364.db
7. Magun R, Verschoor CP, Bowdish DM, Provias J: Mycoplasma pneumoniae, a trigger for Westen Hurst syndrome. Neurol Neuroimmunol Neuroinflamm. 2016, 3:e187. 10.1212/NXI.0000000000000187
8. Tsiodras S, Kelesidis I, Kelesidis T, Stamboulis E, Giamarelou H: Central nervous system manifestations of Mycoplasma pneumoniae infections. J Infect. 2005, 51:543-54. 10.1016/j.jinf.2005.07.005
9. Kashyap S, Sarkar M: Mycoplasma pneumonia: clinical features and management. J Assoc Physicians India. 2010, 27:75-85. 10.4103/0970-2115.63611
10. Tully JG, Rose DL, Whitcomb RF, Wenzel RP: Enhanced isolation of Mycoplasma pneumoniae from throat washings with a newly modified culture medium. J Infect Dis. 1979, 139:478-82. 10.1093/infdis/139.4.478
11. Gavranich JB, Chang AB: Antibiotics for community acquired lower respiratory tract infections (LRTI) secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev. 2005, CD004875. 10.1002/14651858.CD004875.pub2